Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NT-175 · 1 trial · 8 indications
Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175
Per RECIST v1.1 determined by Investigator assessment: * Objective Response Rate (ORR) * Best Overall Response (BOR) * Duration of Response (DOR) * Clinical Benefit Rate (CBR) * Time to Response (TTR) * Progression-free survival (PFS) * Overall Survival (OS)
\- Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175
| Arm | Type | Description |
|---|---|---|
| NT-175 for advanced malignancies | EXPERIMENTAL | TCR T cell therapy product |
| Name | Type | Description |
|---|---|---|
| NT-175 | BIOLOGICAL | * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide * Single infusion Autologous, engineered T Cells targeting TP53 R175H * Post-infusion recombinant interleukin-2 (rIL-2) |
Key Inclusion Criteria (Module 1) * Subjects must be at least 18 years of age * Subject must be diagnosed with one of the histologies below: * NSCLC * Colorectal adenocarcinoma * HNSCC * Pancreatic adenocarcinoma * Breast cancer * Ovarian cancer * Any other solid tumor * Tumors must ...
Top 20 of 84 competitors
NT-175 is an investigational monoclonal antibody being studied for the treatment of non-small cell lung cancer. It is also being evaluated in other advanced solid tumors and myeloid neoplasms, including head and neck squamous cell carcinoma, colorectal carcinoma, pancreatic adenocarcinoma, breast cancer, ovarian cancer, and AML/MDS.
NT-175 targets the TP53 R175H mutation in patients who are positive for the HLA-A*02:01 allele. This mutation is a specific alteration in the p53 tumor suppressor protein, and the drug is designed to recognize and bind to this mutated form.
NT-175 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
NT-175 is currently in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary activity.
NT-175 is being studied in a Phase 1 clinical trial with the identifier NCT05877599. This trial is recruiting 45 adult participants with advanced malignancies that are positive for HLA-A*02:01 and the TP53 R175H mutation. The study is being conducted in the United States.
NT-175 is a distinct investigational monoclonal antibody and is not known to be the same as any other approved or marketed drug. It is being developed specifically for cancers that carry the TP53 R175H mutation in HLA-A*02:01 positive patients.